Edition:
United Kingdom

ArQule Inc (ARQL.OQ)

ARQL.OQ on NASDAQ Stock Exchange Global Market

5.02USD
7:00pm GMT
Change (% chg)

$0.06 (+1.21%)
Prev Close
$4.96
Open
$4.98
Day's High
$5.12
Day's Low
$4.98
Volume
133,252
Avg. Vol
410,573
52-wk High
$7.21
52-wk Low
$2.23

Latest Key Developments (Source: Significant Developments)

Arqule Inc Says Safety Assessment Of Expanded Cohort Was Completed & 65 Mg QD Dose Was Cleared For Safety
Friday, 15 Mar 2019 

March 15 (Reuters) - ArQule Inc ::ARQULE INC - ON MARCH 7, CO REPORTED THAT ONE PATIENT IN COHORT 7 OF ITS PHASE 1 TRIAL WITH ARQ 531 DOSED AT 65MG QD EXPERIENCED A GRADE 3 RASH.ARQULE INC - FURTHER REPORTED THAT COHORT 7 HAD BEEN EXPANDED PER PROTOCOL, AND THAT TWO ADDITIONAL PATIENTS HAD ALREADY CLEARED 65MG QD DOSE.ARQULE INC - ON MARCH 12, 2019, SAFETY ASSESSMENT OF EXPANDED COHORT WAS COMPLETED, AND 65 MG QD DOSE WAS CLEARED FOR SAFETY.ARQULE INC - NOW INTENDS TO OPEN COHORT 8 AND DOSE PATIENTS AT 75MG QD AS WELL AS DOSE INCREASE EXISTING PATIENTS IN COHORT 6 FROM 45MG TO 65MG QD..  Full Article

ArQule Says Chief Financial Officer Robert Weiskopf Has Decided To Retire
Friday, 15 Mar 2019 

March 15 (Reuters) - ArQule Inc ::ARQULE INC - ROBERT WEISKOPF, SENIOR VICE PRESIDENT, CHIEF FINANCIAL OFFICER AND TREASURER, HAS DECIDED TO RETIRE.ARQULE INC - NAMES MARC SCHEGERIN AS CHIEF FINANCIAL OFFICER.  Full Article

ArQule Q4 Loss Per Share $0.08
Thursday, 7 Mar 2019 

March 7 (Reuters) - ArQule Inc ::Q4 LOSS PER SHARE $0.08.ARQULE REPORTS FOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS.SEES FY 2019 REVENUE $3.0 MILLION TO $5.0 MILLION.Q4 EARNINGS PER SHARE ESTIMATE $-0.07 -- REFINITIV IBES DATA.SEES FY 2019 LOSS PER SHARE $0.37 TO $0.39.FY2019 EARNINGS PER SHARE VIEW $-0.34, REVENUE VIEW $5.6 MILLION -- REFINITIV IBES DATA.REVENUES FOR QUARTER ENDED DECEMBER 31, 2018, WERE $2.9 MILLION.ARQULE EXPECTS TO END 2019 WITH BETWEEN $60 AND $63 MILLION IN CASH AND MARKETABLE SECURITIES..  Full Article

Basilea Announces Collaboration To Study Derazantinib And Atezolizumab In Urothelial Cancer
Thursday, 24 Jan 2019 

Jan 24 (Reuters) - ArQule Inc ::BASILEA ANNOUNCES COLLABORATION TO STUDY DERAZANTINIB AND ATEZOLIZUMAB (TECENTRIQ®) IN UROTHELIAL CANCER.ARQULE INC - ENTERED COLLABORATION WITH ROCHE TO STUDY DERAZANTINIB AND ATEZOLIZUMAB (TECENTRIQ®) IN UROTHELIAL CANCER.ARQULE INC - BASILEA EXPECTS TO START A BIOMARKER-DRIVEN MULTI-COHORT PHASE 1/2 STUDY IN MID-2019..ARQULE INC - BASILEA PHARMACEUTICA ENTERED COLLABORATION WITH ROCHE.  Full Article

Arqule Announces Pricing Of $60.5 Mln Public Offering Of Common Stock
Wednesday, 11 Jul 2018 

July 11 (Reuters) - ArQule Inc ::ARQULE ANNOUNCES PRICING OF $60.5 MILLION PUBLIC OFFERING OF COMMON STOCK.SAYS PUBLIC OFFERING OF 11.0 MILLION COMMON SHARES PRICED AT $5.50PER SHARE.  Full Article

Arqule Files Prospectus Related To Seconday Offering Of Up To 10.6 Mln Shares
Thursday, 17 May 2018 

May 17 (Reuters) - ArQule Inc ::ARQULE INC FILES PROSPECTUS RELATED TO OFFERING UP TO 10.6 MILLION SHARES OF CO'S COMMON STOCK BY SELLING STOCKHOLDERS - SEC FILING.  Full Article

Arqule Reports Q1 Loss Per Share Of $0.07
Monday, 7 May 2018 

May 7 (Reuters) - ArQule Inc ::ARQULE REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS.Q1 LOSS PER SHARE $0.07.SEES FY 2018 REVENUE $14 MILLION TO $17 MILLION.Q1 REVENUE $4.138 MILLION.Q1 REVENUE VIEW $2.1 MILLION -- THOMSON REUTERS I/B/E/S.Q1 EARNINGS PER SHARE VIEW $-0.06 -- THOMSON REUTERS I/B/E/S.SEES FY 2018 LOSS PER SHARE $0.18 TO $0.24.ARQULE EXPECTS TO END 2018 WITH BETWEEN $40 AND $42 MILLION IN CASH AND MARKETABLE SECURITIES.  Full Article

Arqule And Basilea Enter Into Exclusive License Agreement For Derazantinib
Tuesday, 17 Apr 2018 

April 17 (Reuters) - ArQule Inc ::ARQULE AND BASILEA ENTER INTO EXCLUSIVE LICENSE AGREEMENT FOR DERAZANTINIB IN THE US, EU, JAPAN AND REST OF WORLD EXCLUDING GREATER CHINA.ARQULE INC - UNDER TERMS OF AGREEMENT, ARQULE WILL RECEIVE AN UPFRONT PAYMENT OF $10 MILLION.ARQULE INC - ARQULE ELIGIBLE TO RECEIVE UP TO $336 MILLION INCLUDING UPFRONT, REGULATORY AND COMMERCIAL MILESTONE PAYMENTS.ARQULE - UNDER CERTAIN CIRCUMSTANCES, CO MAY HAVE OPPORTUNITY TO PROMOTE DERAZANTINIB IN U.S. DIRECTLY.ARQULE - ALSO ENTITLED TO RECEIVE STAGGERED SINGLE-DIGIT TO DOUBLE-DIGIT ROYALTIES ON NET SALES UPON COMMERCIALIZATION.ARQULE - BASILEA WILL BE RESPONSIBLE FOR ALL COSTS AND EXPENSES OF DEVELOPMENT, MANUFACTURE AND COMMERCIALIZATION IN ITS TERRITORY.  Full Article

ArQule Files For Offering Of Up To 17.1 Million Shares
Wednesday, 6 Dec 2017 

Dec 6 (Reuters) - Arqule Inc ::ARQULE INC FILES FOR OFFERING OF UP TO 17.1 MILLION SHARES OF CO'S COMMON STOCK BY SELLING STOCKHOLDERS - SEC FILING.  Full Article

Arqule reports Q3 loss per share $0.09
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - Arqule Inc :Arqule reports third quarter 2017 financial results.Q3 loss per share $0.09.Sees FY 2017 loss per share $0.38 to $0.40.Q3 earnings per share view $-0.11 -- Thomson Reuters I/B/E/S.Arqule Inc - ‍Expects to end 2017 with between $47 and $49 million in cash and marketable securities​.Arqule Inc - ‍For 2017, Arqule expects net use of cash to range between $25 and $27 million​.  Full Article

BRIEF-Basilea Announces Collaboration To Study Derazantinib And Atezolizumab In Urothelial Cancer

* BASILEA ANNOUNCES COLLABORATION TO STUDY DERAZANTINIB AND ATEZOLIZUMAB (TECENTRIQ®) IN UROTHELIAL CANCER